Kestra Medical Technologies filings document the public-company disclosures of a Bermuda-incorporated medical technology issuer listed on Nasdaq under KMTS. Its Form 8-K reports have furnished quarterly and annual financial results, revenue guidance, and Regulation FD disclosures tied to the ASSURE WCD and ACE-PAS post-approval study results.
The company’s proxy materials and annual meeting filings cover board elections, independent auditor ratification, shareholder voting results, and equity compensation matters, including the 2025 Employee Stock Purchase Plan. These records also identify governance procedures and formal shareholder actions for the wearable defibrillator and digital health business.
Kestra Medical Technologies, Ltd. Chief Business Officer Timothy P. Moran sold 3,192 common shares on November 3, 2026, in a nondiscretionary sell-to-cover transaction required to satisfy tax withholding obligations tied to restricted stock unit vesting and settlement. The shares sold at a weighted average price of $29.5589 per share, with reported sale prices ranging from $29.5583 to $29.5595. He held 63,153 common shares directly after the sale.
KESTRA MEDICAL TECHNOLOGIES, LTD. officer Timothy Moran reported a proposed sale of 3,192 common shares, with an aggregate market value of $94,351.63, dated November 3, 2026. The shares are described as from vesting of performance share unit awards granted as part of the issuer’s equity compensation plan.
Kestra Medical Technologies, Ltd. (KMTS) Chief Financial Officer Vaseem Mahboob exercised options for 79,500 common shares at $17 per share across October 27 through October 29, 2026, then sold the same number of shares. Weighted-average sale prices were $30.0435 on October 27, $30.4815 on October 28 and $30.5979 on October 29. The scheduled exercise-and-sale transactions were made under a Rule 10b5-1 trading plan adopted November 5, 2025.
KESTRA MEDICAL TECHNOLOGIES, LTD. director and officer Traci S. Umberger exercised 30,000 options at $17 per share on October 27, 2026, acquiring 30,000 common shares, and sold 30,000 shares at a weighted average price of $30.0294 per share. The scheduled exercise and sale were pursuant to a Rule 10b5-1 plan adopted on July 21, 2026; sale prices ranged from $30.0000 to $30.4202. Her reported option position after the exercise was 411,000 options, including 365,919 fully vested options as of the filing date and 45,081 options vesting in equal monthly installments through March 6, 2027.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) lists officer Mahboob Vaseem's proposed sale of 4,788 common shares on October 29, 2026, in connection with an employee stock-option exercise using a broker-assisted cashless exercise. The proposed sale has an aggregate market value of $146,502.73. The notice also lists seven prior common-stock sales by Vaseem between July 30 and October 28, 2026.
KESTRA MEDICAL TECHNOLOGIES, LTD. officer Mahboob Vaseem filed notice of a proposed sale of 39,903 common shares on October 28, 2026, with an aggregate market value of $1,216,393.08. The notice identifies the shares as related to exercise of employee stock options and describes a broker-assisted cashless exercise. Merrill Lynch is listed as broker and NASDAQ as the exchange.
KESTRA MEDICAL TECHNOLOGIES, LTD. officer Mahboob Vaseem reported a proposed sale of 34,809 common shares on October 27, 2026, with a listed aggregate market value of $1,045,784.87. The notice associates the shares with exercise of employee stock options and lists five prior common-stock sales dated July 30 through August 7, 2026.
Kestra Medical Technologies, Ltd. (KMTS) officer Traci Umberger gave notice of a proposed sale of 30,000 common shares, with an estimated aggregate market value of $900,880.51 and an approximate sale date of October 27, 2026. The shares are identified as arising from the exercise of employee stock options through a broker-assisted cashless exercise; Merrill Lynch is listed as broker.
Kestra Medical Technologies, Ltd. (KMTS) director and officer Traci S. Umberger exercised 100,000 options at an exercise price of $17 per share on October 21, 2026, acquiring 100,000 common shares. She sold 96,404 shares at a weighted average price of $27.1493 and 3,596 shares at $28.0915 under a Rule 10b5-1 trading plan adopted July 21, 2026. Her options following the exercise totaled 441,000.
Kestra Medical Technologies, Ltd. (KMTS) President and Chief Executive Officer Brian Daniel Webster reported two direct sales totaling 15,000 Common Shares on October 20, 2026: 13,316 shares at a weighted average price of $29.5172 and 1,684 shares at $29.8920. Both sales were made under a Rule 10b5-1 trading plan adopted on July 21, 2026.